As of December 31, 2024, Elanco's net leverage ratio was 4.3x adjusted EBITDA, flat to September 30, 2024. The company anticipates a headwind to revenue of approximately $110 million from the ...

GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences. Live audio ...

Elanco Animal Health Incorporated ... K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination ...

Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free ...

Learn more about whether Elanco Animal Health Incorporated or Harmony Biosciences Holdings, Inc. is a better investment based ...

In this article, we are going to take a look at where Elanco Animal Health Incorporated (NYSE:ELAN) stands against the other stocks. Ten firms ended Tuesday suffering a sell-off, as investor ...

Elanco missed analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $1.03 billion, down 3.6% year on year. It was a mixed quarter for the company, with a solid beat of ...

In its fourth quarter 2024 investor letter, Hardman Johnston Global Equity Strategy emphasized stocks such as Elanco Animal Health Incorporated (NYSE:ELAN). Elanco Animal Health Incorporated (NYSE ...

Elanco Animal Health Incorporated has a 52-week ... Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology ...